Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative medications work by mimicking the inherent actions of GLP-1, a hormone secreted by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these substances increase insulin production and suppress

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting considerable weight decrease – they exhibit intriguing contrasts in th